Erlotinib and radiation therapy for elderly patients with esophageal cancer - Clinical and correlative results from a prospective multicenter phase 2 trial

Oncology (Switzerland)

Volumn 85, Issue 1, 2013, Pages 53-58

  Iyer, Renuka ^a   Chhatrala, Ravi ^b   Shefter, Tracey ^c   Yang, Gary ^d   Malhotra, Usha ^a   Tan, Wei ^a   Levea, Charles ^a   Robins, Melissa ^a   Khushalani, Nikhil ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d LOMA LINDA UNIVERSITY   (United States)

Author keywords

Elderly patients; Epidermal growth factor receptor; Erlotinib; Esophageal cancer; Radiotherapy

Indexed keywords

ERLOTINIB;

AGED; ANOREXIA; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOMA IN SITU; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEATH; DEHYDRATION; DIARRHEA; DRUG WITHDRAWAL; ELECTROCORTICOGRAPHY; ENDOSCOPY; ESOPHAGUS; ESOPHAGUS CANCER; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; HEART INFARCTION; HUMAN; HUMAN TISSUE; LOWER ESOPHAGUS SPHINCTER; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIATION DOSE; RASH; RESPIRATORY DISTRESS; SMOKING; SQUAMOUS CELL CARCINOMA; THORACIC ESOPHAGUS;

EID: 84880183210     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000351617     Document Type: Article

References (19)

1. Siegel R, Ward E, Brawley O, Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
2. Holmes RS, Vaughan TL: Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol 2007; 17: 2-9.
3. Lorchel F, Bosset M, Crehange G, Buffet-Miny J, Puyraveau M, Mercier M, Bosset J: Chemoradiation for esophageal cancer (EC) in elderly patients over 75 years: a phase II study. J Clin Oncol 2004; 22(14S):4155.
4. Sabel M, Smith J, Nava H, Mollen K, Douglass H, Gibbs J: Esophageal resection for carcinoma in patients older than 70 years. Ann Surg Oncol 2002; 9: 210-214.
5. Poon RTP, Law SYK, Chu KM, Branicki FJ, Wong J: Esophagectomy for carcinoma of the esophagus in the elderly: results of current surgical management. Ann Surg 1998; 227: 357-364.
6. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL: Chemoradiotherapy of locally advanced esophageal cancer. JAMA 1999; 281: 1623-1627.
7. Kitagawa Y, Ueda M, Ando N, Ozawa S, Shimizu N, Kitajima M: Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin Cancer Res 1996; 2: 909-914.
8. Gibson MK, Abraham SC, Wu T-T, Burtness B, Heitmiller RF, Heath E, Forastiere A: Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 2003; 9: 6461-6468.
9. Grana TM, Sartor CI, Cox AD: Epidermal growth factor receptor autocrine signaling in RIE-1 cells transformed by the Ras oncogene enhances radiation resistance. Cancer Res 2003; 63: 7807-7814.
10. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, Neveu M, Pollack VA, Pustilnik LR, Reynolds MM, Sloan D, Theleman A, Miller P: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997; 57: 4838-4848.
11. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-28.
12. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu C-T, Ganul V, Roh J-K, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373: 1525-1531.
13. Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J, Benedetti JK, Baker AF, Hackett CB, Urba SG, Zaner KS, Blanke CD, Abbruzzese JL: Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006; 24: 4922-4927.
14. Dobelbower MC, Russo SM, Raisch KP, Seay LL, Clemons LK, Suter S, Posey J, Bonner JA: Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study. Anticancer Drugs 2006; 17: 95-102.
15. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-656.
16. Darling G, Eton DT, Sulman J, Casson AG, Cella D: Validation of the functional assessment of cancer therapy esophageal cancer subscale. Cancer 2006; 107: 854-863.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
18. Zhai Y, Hui Z, Wang J, Zou S, Liang J, Wang X, Lv J, Chen B, Zhu H, Wang L: Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study. Dis Esophagus 2012, E-pub ahead of print.
19. Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K, Cagnoni PJ: Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006; 12: 2166-2171.